JPRN-jRCT2080223846未知1 期
Phase 1 study of DS-3201b to assess the effects of itraconazole and fluconazole on the pharmacokinetics of single oral administration of DS-3201b tablets in healthy Japanese subjects
试验速览
- 阶段
- 1 期
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 45age old（—）
- 性别
- Male
入选标准
- •1.Japanese males
- •2.Age: >=20 and =<45 years (at the time of informed consent)
- •3.Body mass index (BMI) = Body weight (kg) / (Height [m])2: >=18.5 and <25.0 (at screening)
排除标准
- •1.Having a history of hypersensitivity to drugs or other substances or being idiosyncratic (eg, having penicillin allergy)
- •2.Having alcohol or drug dependence
研究者
相似试验
已完成
1 期
Phase 1 Study of DS-3201b to Assess the Effects of Multiple Oral Administration of Rifampicin on the Pharmacokinetics of Single Oral Administration of DS-3201b Tablets in Healthy Japanese SubjectsHealthy volunteersJPRN-jRCT2080225242DAIICHI SANKYO Co.,Ltd.20
已完成
1 期
Phase 1 study of DS-3201b to evaluate the effect of food (low-fat meal) on the pharmacokinetics in healthy subjectsHealthy subjectsJPRN-jRCT2071200043agao Kiminori28
进行中（未招募）
不适用
Phase IIa study to investigate the efficacy of NOX-H94 in the treatment of anemia in patients with cancer.anemia of chronic disease in patients with cancerMedDRA version: 16.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864MedDRA version: 16.0Level: LLTClassification code 10054310Term: Anemia of chronic diseaseSystem Organ Class: 100000004851EUCTR2012-001525-27-ATOXXON Pharma AG48
进行中（未招募）
1 期
Phase IIa study to investigate the efficacy of NOX-H94 in the treatment of anemia in patients with cancer.EUCTR2012-001525-27-BGOXXON Pharma AG48
招募中
2 期
Phase IIa Study to Characterize the Effects of the Spiegelmer® NOX H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or LymphomaD63.0Anaemia in neoplastic diseaseAnemia of Chronic DiseaseDRKS00004366OXXON Pharma AG48